Learn about AFCR’s support for the development and conversion of exciting laboratory breakthroughs into new and more effective cancer treatments, screenings and preventive technologies. Listed in this section are Translational Research initiatives which are or have been sponsored by AFCR, made possible with our dedicated donors’ support.

Target Immune Therapy to Cancer Cells

Company Overview Innovation: Targeting Immune Engagement Targeted Cancer(s): Gastrointestinal cancers, including pancreas, stomach, liver and bowel. Scientific Leadership/Leadership: Prof. John Luk, DMedSc., EMBA, CEO and Founder Dr. Dennis Wong, MD,…

Read more

YIV-906: Therapeutics—first-in-class botanical cancer platform drug

Ongoing since 2020 Company Overview Innovation: Therapeutics—first-in-class botanical cancer platform drug Targeted Cancer(s): Liver cancer Scientific Leadership: Yung-Chi Cheng, Ph.D.; Shwu-Huey Liu, Ph.D. Stage of Project: Phase II clinical trial about to commence; orphan…

Read more

DotBio: Multi-functional antibodies to target cancer on multiple fronts

Advanced cancers typically suppress the immune response by multiple mechanisms. By carefully engineering multi-functional antibody therapies, there is the potential for more effective treatment.

Read more

Determining the Risk of Hereditary Breast and Ovarian Cancer (HBOC) in China

Understanding the risk of breast cancer in the Chinese population is very important due to the exponential increase in incidence...

Read more